Skip to main content

ScienceDex / Researcher record

Gentry, W Brooks

From the FY2021 NIH awards this investigator leads as contact PI. The department is the award's.

FY2021 NIH rank #186
  • Top 1% Funded
  • Rising Star
  • Sustained Excellence
  • Program Leader
  • Long-Funded

NIH Funding · FY2021

$11.5M
Full award amounts, FY2021
3
Records listing this PI
#186
By linked amount among FY2021 PIs
2001
ScienceDex PI coverage

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

Linked awards ($M)Award-linked rank
View yearly values
Award-linked funding and rank by fiscal year
Fiscal yearLinked awardsRecordsRank
2001$175,5001#22,525
2002$175,5001#24,410
2009$1,194,6591#6,429
2010$2,769,4781#2,185
2014$1,287,4781#4,978
2015$1,594,8731#3,809
2016$2,085,1331#2,576
2017$4,796,7172#539
2018$2,735,8561#1,649
2019$2,368,2002#2,406
2021$11,513,3943#186
2022$6,433,7112#487
2023$4,609,9021#852

Award activity

Awards through the years

NIH award records listing this researcher in each fiscal year.

  1. FY20011 record
  2. FY20021 record
  3. FY20091 record
  4. FY20101 record
  5. FY20141 record
  6. FY20151 record
  7. FY20161 record
  8. FY20172 records
  9. FY20181 record
  10. FY20192 records
  11. FY2021 · selected3 records
  12. FY20222 records
  13. FY20231 record

Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Gentry, W Brooks. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2021 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets About this stat →

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Publications

Loading publications…

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID unavailableSearch this ID in NIH RePORTER
ORCID iD
No ORCID iD on recordA researcher can add one by claiming this profile.
ScienceDex PI coverage
FY2001 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.

FY2021 award records by amount

NIH award records listing Gentry, W Brooks as a PI. Multi-PI records show the full award amount for context.

  • 1U01DA055481-01U01Contact PI
    OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder
    $4.6M
    award amount
  • 5U01DA053043-02U01Contact PI
    Meth-OD: A PHASE 2A STUDY OF IXT-M200 IN METHAMPHETAMINE OVERDOSE PATIENTS
    $3.8M
    award amount
  • 5U01DA051078-02U01Contact PI
    Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization
    $3.2M
    award amount

Award organization

Organizations that administered FY2021 awards listing Gentry, W Brooks as a PI.

FY2021 award administered by Intervexion Therapeutics, LLC (AR).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2001
    First NIH Award
    Intervexion Therapeutics, LLC
  2. 2009
    $500K Cumulative Funding
  3. 2009
    $1M Cumulative Funding
  4. 2009
    Entered Top 50% Nationally
    Ranked #6429
  5. 2010
    $2M Cumulative Funding
  6. 2010
    Entered Top 25% Nationally
    Ranked #2185
  7. 2014
    $5M Cumulative Funding
  8. 2016
    Program/Center Grant Leader
  9. 2017
    $10M Cumulative Funding
  10. 2017
    Entered Top 10% Nationally
    Ranked #539
  11. 2017
    Entered Top 5% Nationally
    Ranked #539
  12. 2021
    $25M Cumulative Funding
  13. 2021
    Entered Top 1% Nationally
    Ranked #186